pharmaceutical firms
The Enforcement of Mandatory Disclosure Rules
with P González and N Porteiro, Journal of Public Economics, 2018, DOI
The most recent unpublished version is here: DahmEtAlEnforcementDisclosure (August 2018).
Click here for longer summary.
This paper examines the incentives of firms to invest in information about product risk and to disclose its findings. Continue reading
Implementing Registries and Results Databases of Clinical Trials: Is There a Side Effect?
with P González and N Porteiro, Expert Review of Pharmacoeconomics & Outcomes Research, 2010, DOI
Many parts of the world are currently witnessing a controversial discussion concerning the appropriate design of the environment for clinical trials. Continue reading
Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge
with P González and N Porteiro, Journal of Health Economics, 2009, DOI
Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined the need for more transparency in clinical trials. We provide a theoretical framework Continue reading
Matthias Dahm's web site 